Sarepta Rises on Muscular Dystrophy Results: Boston Mover

Sarepta Therapeutics Inc. tripled in trading after its drug for Duchenne muscular dystrophy helped patients walk farther in a study and restored a key protein lacking in some of those with the disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.